Plerixafor
- Generic Name
- Plerixafor
- Brand Names
- Mozobil, Plerixafor Accord
- Drug Type
- Small Molecule
- Chemical Formula
- C28H54N8
- CAS Number
- 110078-46-1
- Unique Ingredient Identifier
- S915P5499N
- Background
Plerixafor is a small-molecule inhibitor of C-X-C chemokine receptor type 4 (CXCR4) that acts as a hematopoietic stem cell mobilizer. It is used to stimulate the release of stem cells from the bone marrow into the blood in patients with non-Hodgkin's lymphoma (NHL) and multiple myeloma to stimulate their immune system. These stem cells are then collected and...
- Indication
Plerixafor is indicated in combination with granulocyte-colony stimulating factor (G-CSF) to mobilize hematopoietic stem cells (HSCs) to the peripheral blood for collection and subsequent autologous transplantation in patients with non-Hodgkin’s lymphoma or multiple myeloma.
- Associated Conditions
- -
- Associated Therapies
- Mobilization of hematopoietic stem cells
Gene Editing For Sickle Cell Disease
- Conditions
- Interventions
- First Posted Date
- 2024-07-17
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- St. Jude Children's Research Hospital
- Target Recruit Count
- 25
- Registration Number
- NCT06506461
- Locations
- 🇺🇸
St. Jude Children's Research Hospital, Memphis, Tennessee, United States
Protocol Title: Safety and Feasibility of Autologous CD34+ Hematopoietic Stem Cells Mobilization and Apheresis in Participants With RUNX1 Familial Platelet Disorder
- Conditions
- Interventions
- First Posted Date
- 2024-05-16
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 4
- Registration Number
- NCT06414889
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
Base Editing for Mutation Repair in Hematopoietic Stem & Progenitor Cells for X-Linked Chronic Granulomatous Disease
- First Posted Date
- 2024-03-22
- Last Posted Date
- 2024-12-19
- Target Recruit Count
- 10
- Registration Number
- NCT06325709
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Pre-transplant Purging and Post-transplant MRD-guided Maintenance Therapy With Elranatamab in Patients With High-risk Multiple Myeloma
- First Posted Date
- 2024-01-17
- Last Posted Date
- 2024-11-28
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 40
- Registration Number
- NCT06207799
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
Pilot Study of Memory-like Natural Killer (ML NK) Cells After TCRαβ T Cell Depleted Haploidentical Transplant in AML
- Conditions
- Interventions
- Drug: Rabbit Anti thymocyte globulinDrug: PlerixaforBiological: Granulocyte Colony-Stimulating FactorDrug: BusulfanDrug: FludarabineDrug: ThiotepaDrug: MelphalanBiological: TCR alpha beta / CD19+ depleted haploidentical hematopoietic progenitor cell graftBiological: memory-like natural killer cellsBiological: IL-2Device: CliniMACS
- First Posted Date
- 2023-12-06
- Last Posted Date
- 2024-05-17
- Lead Sponsor
- Washington University School of Medicine
- Target Recruit Count
- 48
- Registration Number
- NCT06158828
- Locations
- 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States
Plerixafor Plus Donor Lymphocyte Infusion for Relapsed Acute Leukemia After Allo-HSCT
- Conditions
- Interventions
- First Posted Date
- 2023-11-21
- Last Posted Date
- 2023-11-21
- Lead Sponsor
- The First Hospital of Jilin University
- Target Recruit Count
- 28
- Registration Number
- NCT06141304
- Locations
- 🇨🇳
First Hospital of Jilin University, Changchun, Jilin, China
Trial of Allogeneic Reduced-Intensity, HLA-Haploidentical Allogeneic Hematopoietic Cell Bone Marrow Transplantation Followed by Graft-versus-Host-Disease (GVHD) Prophylaxis With Cyclophosphamide, Bortezomib and Maraviroc for Hematologic Malignancies ...
- Conditions
- Interventions
- First Posted Date
- 2022-07-22
- Last Posted Date
- 2024-12-11
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 265
- Registration Number
- NCT05470491
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Study of MGTA-145 and Plerixafor in Patients With Sickle Cell Disease
- First Posted Date
- 2022-07-06
- Last Posted Date
- 2024-01-11
- Lead Sponsor
- Ensoma
- Target Recruit Count
- 1
- Registration Number
- NCT05445128
- Locations
- 🇺🇸
National Institutes of Health, Bethesda, Maryland, United States
🇺🇸Boston Children's Hospital, Boston, Massachusetts, United States
🇺🇸St. Jude Children's Research Hospital, Memphis, Tennessee, United States
Addition of JSP191 (C-kit Antibody) to Nonmyeloablative Hematopoietic Cell Transplantation for Sickle Cell Disease and Beta-Thalassemia
- First Posted Date
- 2022-05-03
- Last Posted Date
- 2024-12-02
- Target Recruit Count
- 90
- Registration Number
- NCT05357482
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Bone Marrow Derived Stem Cells Mobilization for Treatment of Abnormal Endometrium
- Conditions
- Interventions
- First Posted Date
- 2022-04-25
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Hugh Taylor
- Target Recruit Count
- 30
- Registration Number
- NCT05343572
- Locations
- 🇺🇸
Yale Fertility Center, Orange, Connecticut, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.